Rater Performance Central Monitoring (RPCM) Programs in Early Symptomatic Alzheimer Disease Trials 

Cogstate had the pleasure of co-authoring a poster presented at #ADPD24 highlighting learnings from a rater performance monitoring program used in TRAILBLAZER-ALZ 2, a Phase 3 Clinical Trial of Donanemab in Early Symptomatic Alzheimer Disease.
Rater performance was analyzed across four outcome measures that were part of the study and frequently leveraged in AD clinical trials:
♦️ ADAS-Cog 13
♦️ ADCS-ADL
♦️ CDR
♦️ MMSE
Findings from the data indicate the importance of centrally monitoring rater performance to ensure data integrity and consistency throughout studies, particularly those that are multi-country and utilizing complex & lengthy scales.
#neuroscience #cognition #alzheimer #alzheimers #clinicaltrials #cogstate

Наука